Erschienen in:
31.01.2023 | Hepatobiliary Tumors
The Current State of Liver Transplantation for Colorectal Liver Metastases in the United States: A Call for Standardized Reporting
verfasst von:
Kazunari Sasaki, MD, Luis I. Ruffolo, MD, Michelle H. Kim, MD, Masato Fujiki, MD, PhD, Koji Hashimoto, MD, PhD, Yuki Imaoka, MD, PhD, Marc L. Melcher, MD, PhD, Federico N. Aucejo, MD, Koji Tomiyama, MD, Roberto Hernandez-Alejandro, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2023
Einloggen, um Zugang zu erhalten
Abstract
Background
Current success in transplant oncology for select liver tumors, such as hepatocellular carcinoma, has ignited international interest in liver transplantation (LT) as a therapeutic option for nonresectable colorectal liver metastases (CRLM). In the United States, the CRLM LT experience is limited to reports from a handful of centers. This study was designed to summarize donor, recipient, and transplant center characteristics and posttransplant outcomes for the indication of CRLM.
Methods
Adult, primary LT patients listed between December 2017 and March 2022 were identified by using United Network Organ Sharing database. LT for CRLM was identified from variables: “DIAG_OSTXT”; “DGN_OSTXT_TCR”; “DGN2_OSTXT_TCR”; and “MALIG_TY_OSTXT.”
Results
During this study period, 64 patients were listed, and 46 received LT for CRLM in 15 centers. Of 46 patients who underwent LT for CRLM, 26 patients (56.5%) received LTs using living donor LT (LDLT), and 20 patients received LT using deceased donor (DDLT) (43.5%). The median laboratory MELD-Na score at the time of listing was statistically similar between the LDLT and DDLT groups (8 vs. 9, P = 0.14). This persisted at the time of LT (8 vs. 12, P = 0.06). The 1-, 2-, and 3-year, disease-free, survival rates were 75.1, 53.7, and 53.7%. Overall survival rates were 89.0, 60.4, and 60.4%, respectively.
Conclusions
This first comprehensive U.S. analysis of LT for CRLM suggests a burgeoning interest in high-volume U.S. transplant centers. Strategies to optimize patient selection are limited by the scarce oncologic history provided in UNOS data, warranting a separate registry to study LT in CRLM.